Home
|
English
|
简体中文
|
Sign In
or
Sign Up
ESG Investing
What is ESG?
History of ESG Investment
ESG Investment Approach
ESG Investment Practice
Standards and Initiatives
ESG cartoon character (CN)
ESG Ratings & Data
ESG Rating Methodology
STαR ESG Data Platform
ESG Risk Radar System
ESG Investment Strategy
Proactive ESG Rating
Chinese Company's ESG Rating Search
Sustainable Finance
ESG Due Diligence
ESRM
Capacity Building
Policy Advisory
China Green Finance Policy Database
ESG Verification
AA1000 Assurance Service
Green Bond Evaluation
Climate Change
Carbon Footprint
Physical Risks
PANDA Climate Data
Climate Scenario Analysis
Climate Stress Testing
Publications
Sustainable Investment Review
ESG Performance Research
Climate Change
Green Bonds
ESG Issues
Industry Research
Other Research
News
About Us
Introduction
Contact Us
SynTao GF Team
Join Us
Internships
STGF WeChat Account (Chinese only)
STGF WeChat Channels (Chinese only)
China SIF
News
Press Releases
Professional Activities
ESG Research
ESG评级洞察
ESG风险扫描
融绿气候研究所
可持续投资研究
Press Releases
Home
>
News
>
Press Releases
After Vaccine Scandal: A Review on Fake Vaccine Controversies of Listed Companies in the Past Eight Years
Views : 4721
Update time : 2018-07-23 16:43:00
Chinese version only.
Previous :
STGF ESG Data of Listed Companies in China Available on Wind Financial Terminal
Next :
SynTao Green Finance supported ACGA's China Report
